FDA Approves First RAS-Targeted Drug for Pancreatic Cancer, Nearly Doubling Survival

For over four decades, pancreatic cancer research has been haunted by a frustrating biological lock. More than 90 percent of pancreatic tumors are driven by mutations in the RAS family of proteins, which act as a stuck accelerator for tumor growth. Yet despite knowing exactly what causes the disease, scientists have long considered these proteins "undruggable"—too smooth and elusive for medications to bind to. This left patients with advanced disease relying almost entirely on standard, often grueling, chemotherapy regimens.[2][3]

That decades-long standoff ended on Wednesday. The U.S. Food and Drug Administration (FDA) approved daraxonrasib, sold under the brand name Rasonque, as the first-ever targeted therapy for metastatic pancreatic adenocarcinoma. The once-daily pill acts as a "molecular glue," finally successfully binding to and blocking the rogue RAS proteins.[1][2]

The approval arrives six and a half months ahead of the agency's deadline, reflecting the urgent need for better options in a disease that remains the fourth leading cause of cancer deaths in the United States. "This drug showed unprecedented results in an area of high unmet need," noted Dr. Angelo de Claro, director of the FDA's Oncology Center of Excellence, highlighting the agency's push to accelerate treatments for life-threatening conditions.[2]

For patients and their families, the practical implications of this breakthrough are profound. In the pivotal Phase 3 RASolute 302 trial, which enrolled 500 adults whose cancer had stopped responding to prior treatments, daraxonrasib nearly doubled survival times. Patients receiving the new targeted pill lived for a median of 13.2 months, compared to 6.7 months for those who received standard chemotherapy.[1][2]

Beyond extending life, the shift from broad-spectrum chemotherapy to a targeted oral pill offers a different day-to-day experience for patients. While standard chemotherapy attacks all rapidly dividing cells, daraxonrasib hones in specifically on the RAS pathway, offering a more precise mechanism of action.[1][3]

However, the medication is not without side effects, and patients will need to work closely with their care teams to manage them. The most common adverse events reported during the trials included rash, diarrhea, mouth inflammation, nausea, and fatigue. Despite these challenges, the targeted approach generally spares patients some of the systemic toxicity associated with traditional multi-agent chemotherapy, allowing for a potentially better quality of life during treatment.[2]

Currently, Rasonque is approved specifically for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy, or those who cannot tolerate multi-agent chemotherapy. Pancreatic adenocarcinoma accounts for the vast majority—up to 95 percent—of the roughly 67,000 pancreatic cancer cases diagnosed annually in the U.S., making this approval highly relevant to most patients facing the disease.[2]

Looking ahead, the approval of daraxonrasib is likely just the beginning of a broader shift in how RAS-driven cancers are treated. Clinical trials are already underway testing the drug in earlier stages of pancreatic cancer, as well as in other difficult-to-treat malignancies like RAS-mutated lung and colorectal cancers.[1][3]

For now, the arrival of Rasonque offers a reassuring milestone: a historically intractable cancer is finally yielding to precision medicine. Patients who previously had few places to turn after initial treatments failed now have a scientifically tailored option that directly targets the root driver of their disease, transforming a rapidly fatal diagnosis into a condition that can be managed for significantly longer.[1][3]